Spoken Alpha
MCRB
Seres Therapeutics, Inc.
Overview
Seres Therapeutics, Inc is a Healthcare company operating in Biotechnology with a $45.0M market cap.
Most recent reported earnings: Q3 FY2026 (Nov 3, 2026).
19 earnings calls indexed on Spoken Alpha.
Behavioral analysis
Management language signature
Disclosures
Investor Relations
Extracted from Unknown source, 2026-08-30.
Transcripts
Recent earnings calls
Most recent calls indexed for this ticker. Open any call to drill into prepared remarks and Q&A.
- Q3 FY2025Earnings2025-11-052 Q&A exchanges
- Q2 FY2025Earnings2025-08-061 Q&A exchange
- Q1 FY2025Earnings2025-05-0710 Q&A exchanges
- Q4 FY2024Earnings2025-03-138 Q&A exchanges
- Q3 FY2024Earnings2024-11-136 Q&A exchanges
- Q2 FY2024Earnings2024-08-138 Q&A exchanges
- Q1 FY2024Earnings2024-05-089 Q&A exchanges
- Q4 FY2023Earnings2024-03-0517 Q&A exchanges
- Q3 FY2023Earnings2023-11-049 Q&A exchanges
- Q2 FY2023Earnings2023-08-0810 Q&A exchanges
- Q1 FY2023Earnings2023-05-0914 Q&A exchanges
- Q4 FY2022Earnings2023-03-077 Q&A exchanges
- Q3 FY2022Earnings2022-11-0216 Q&A exchanges
- Q2 FY2022Earnings2022-08-0315 Q&A exchanges
- Q1 FY2022Earnings2022-05-0412 Q&A exchanges
- Q4 FY2021Earnings2022-03-0119 Q&A exchanges
- Q3 FY2021Earnings2021-11-1013 Q&A exchanges
- Q2 FY2021Earnings2021-08-0312 Q&A exchanges
- Q1 FY2021Earnings2021-05-0418 Q&A exchanges
History
Earnings history
- Q3 FY20262026-11-03EPS— vs $-1.34—Rev— vs ——EODHD
- Q2 FY20262026-08-04EPS$-1.50 vs $-2.07+27.5%Rev$736.0K vs ——EODHD
- Q1 FY20262026-05-04EPS$-2.08 vs $-1.88-10.6%Rev$358.0K vs ——EODHD
- Q4 FY20252026-03-11EPS$-1.76 vs $-1.60-10.0%Rev$438.0K vs ——EODHD
- Q3 FY20252025-11-04EPS$0.94 vs $0.05+100.0%Rev$351.0K vs ——EODHD
- Q2 FY20252025-08-05EPS$-2.27 vs $-2.270.0%Rev$0 vs ——EODHD
- Q1 FY20252025-05-06EPS$-2.24 vs $1.97-100.0%Rev$0 vs ——EODHD
- Q4 FY20242025-03-02EPS$-0.11 vs $-0.20+44.8%Rev$6.0M vs ——EODHD
- Q3 FY20242024-11-12EPS$-6.60 vs $-0.04-100.0%Rev$0 vs ——EODHD
- Q2 FY20242024-08-12EPS$-4.40 vs $-5.91+25.6%Rev$0 vs ——EODHD
- Q1 FY20242024-05-07EPS$-5.40 vs $-7.25+25.5%Rev$0 vs ——EODHD
- Q4 FY20232024-03-04EPS$-0.32 vs $-0.50+36.0%Rev$64.0K vs ——EODHD
- Q3 FY20232023-11-01EPS$-7.40 vs $-10.65+30.5%Rev$310.0K vs ——EODHD
- Q2 FY20232023-08-07EPS$7.20 vs $10.97-34.4%Rev$126.5M vs ——EODHD
- Q1 FY20232023-05-08EPS$-11.40 vs $-10.85-5.1%Rev$-522.0K vs ——EODHD
- Q4 FY20222023-03-06EPS$-0.54 vs $-0.46-17.4%Rev$975.0K vs ——EODHD
- Q3 FY20222022-11-01EPS$-9.80 vs $-9.44-3.8%Rev$3.4M vs ——EODHD
- Q2 FY20222022-08-02EPS$-14.00 vs $-12.30-13.8%Rev$1.2M vs ——EODHD
- Q1 FY20222022-05-03EPS$-12.20 vs $-10.04-21.5%Rev$1.5M vs ——EODHD
- Q4 FY20212022-02-28EPS$-0.52 vs $-0.44-18.2%Rev$7.2M vs ——EODHD
| Period | Reported | EPS actual | EPS consensus | EPS surprise | Revenue actual | Revenue consensus | Rev. surprise | Source |
|---|---|---|---|---|---|---|---|---|
| Q3 FY2026 | 2026-11-03 | — | $-1.34 | — | — | — | — | EODHD |
| Q2 FY2026 | 2026-08-04 | $-1.50 | $-2.07 | +27.5% | $736.0K | — | — | EODHD |
| Q1 FY2026 | 2026-05-04 | $-2.08 | $-1.88 | -10.6% | $358.0K | — | — | EODHD |
| Q4 FY2025 | 2026-03-11 | $-1.76 | $-1.60 | -10.0% | $438.0K | — | — | EODHD |
| Q3 FY2025 | 2025-11-04 | $0.94 | $0.05 | +100.0% | $351.0K | — | — | EODHD |
| Q2 FY2025 | 2025-08-05 | $-2.27 | $-2.27 | 0.0% | $0 | — | — | EODHD |
| Q1 FY2025 | 2025-05-06 | $-2.24 | $1.97 | -100.0% | $0 | — | — | EODHD |
| Q4 FY2024 | 2025-03-02 | $-0.11 | $-0.20 | +44.8% | $6.0M | — | — | EODHD |
| Q3 FY2024 | 2024-11-12 | $-6.60 | $-0.04 | -100.0% | $0 | — | — | EODHD |
| Q2 FY2024 | 2024-08-12 | $-4.40 | $-5.91 | +25.6% | $0 | — | — | EODHD |
| Q1 FY2024 | 2024-05-07 | $-5.40 | $-7.25 | +25.5% | $0 | — | — | EODHD |
| Q4 FY2023 | 2024-03-04 | $-0.32 | $-0.50 | +36.0% | $64.0K | — | — | EODHD |
| Q3 FY2023 | 2023-11-01 | $-7.40 | $-10.65 | +30.5% | $310.0K | — | — | EODHD |
| Q2 FY2023 | 2023-08-07 | $7.20 | $10.97 | -34.4% | $126.5M | — | — | EODHD |
| Q1 FY2023 | 2023-05-08 | $-11.40 | $-10.85 | -5.1% | $-522.0K | — | — | EODHD |
| Q4 FY2022 | 2023-03-06 | $-0.54 | $-0.46 | -17.4% | $975.0K | — | — | EODHD |
| Q3 FY2022 | 2022-11-01 | $-9.80 | $-9.44 | -3.8% | $3.4M | — | — | EODHD |
| Q2 FY2022 | 2022-08-02 | $-14.00 | $-12.30 | -13.8% | $1.2M | — | — | EODHD |
| Q1 FY2022 | 2022-05-03 | $-12.20 | $-10.04 | -21.5% | $1.5M | — | — | EODHD |
| Q4 FY2021 | 2022-02-28 | $-0.52 | $-0.44 | -18.2% | $7.2M | — | — | EODHD |
Source: EODHD. MCRB reported actuals as published; sparse fields render as —.
Top executives
Executives who appear on this company's earnings calls in our corpus, with role and tenure sourced from SEC filings. Click any name for the full role timeline and call appearance history. Per-executive behavioral deviation metrics are available to research subscribers.
- Richard N KenderSee Remarks6 mono recorded callsCurrent
- Kelly BradySee Remarks6 mono recorded callsCurrent
- Marella ThorellSee Remarks2 yr 6 mo7 callsCurrent
- Teresa L YoungSee Remarks6 yr 3 mo6 callsCurrent
- Matthew R HennSee Remarks6 yr 8 mo17 callsCurrent
- Thomas DesrosierSee Remarks10 yr 4 mono recorded callsCurrent
Peers
Other companies in Healthcare
Sector peers tracked by Spoken Alpha. Each links to the same machine-readable IR surface — earnings calls, executives, and accountability scores.
API
For developers and AI agents
The same data on this page is available as a machine-readable feed via the Spoken Alpha API. One call returns the IR URL, recent transcripts, and accountability scores for MCRB.
$ curl https://api.spokenalpha.com/v1/companies/MCRBFAQ
Frequently asked about MCRB
Where can I find Seres Therapeutics, Inc.'s (MCRB) earnings call transcripts?
Spoken Alpha indexes MCRB's earnings call transcripts at https://spokenalpha.com/companies/MCRB. Each call links to attributed speakers and parsed analyst Q&A. Seres Therapeutics, Inc.'s own investor relations page is at https://ir.serestherapeutics.com/.
When was Seres Therapeutics, Inc.'s most recent earnings call?
Seres Therapeutics, Inc. (MCRB) held its most recent earnings call on 2025-11-05, covering fiscal Q3 2025.
What sector is MCRB in?
Seres Therapeutics, Inc. (MCRB) operates in the Healthcare sector (Biotechnology industry).